Notably, abundant co-expression of Tim-3, LAG-3, and PD-1 is frequently observed in advanced cancers, where these receptors collaboratively contribute to clinical resistance against PD-1/PD-L1 blockade therapy (16–19). Here, HAVCR2 is linked to cancer.